Academia Open
Vol 10 No 1 (2025): June (In Progress)
Medicine

Relationship Coagulation Indicator with Hyperglycemia and Hyperlipidemia in Diabetes Mellitus Disease
Hubungan Indikator Koagulasi dengan Hiperglikemia dan Hiperlipidemia pada Penyakit Diabetes Melitus


View Article
  • Wisam Abdan Wawi AL Abdullah*
*

(*) Corresponding Author
Picture in here are illustration from public domain image or provided by the author, as part of their works
DOI: https://doi.org/10.21070/acopen.10.2025.10499
Published January 19, 2025
Keywords
  • diabetes,
  • Prothrombin time,
  • activated partial thromboplastin,
  • atherogenic index of plasma,
  • coagulation factors
How to Cite
Abdullah, W. A. W. A. (2025). Relationship Coagulation Indicator with Hyperglycemia and Hyperlipidemia in Diabetes Mellitus Disease. Academia Open, 10(1), 10.21070/acopen.10.2025.10499. https://doi.org/10.21070/acopen.10.2025.10499

Copyright (c) 2025 Wisam Abdan Wawi AL Abdullah

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

Metabolism dysfunction including hyperglycemia and hyperlipidemia in diabetes mellitus case are crucial factors in developing vascular diseases, platelet activation and hypercoagutable state. Increasing coagulation factors and hypercoagulability were reported in diabetes mellitus patients which due to increase of coagulation factors that resulted in prothrombotic state and extension of thrombolytic lysis in diabetes patients. Thus, this works amid to exam the association between coagulation index's with hyperglycemia and dyslipidemia in diabetes mellitus patients. FBG, HbA1c, PT, APTT, INR, D-dimer, platelets and MPV values were showed significant increase in diabetic's patients compared with their levels of healthy. Lipids profiles, AIP and TC/HDL ratio were found significantly higher in patients they were suffering from diabetic. Person correlation analysis presented a strong association between prothrombin time and (FBG, PLT, TC and LDL). MPV and AIP were a moderate positive correlate with prothrombin time. Prothrombin time was a weak correlated with HbA1c, TG, HDL and TC/HDL ratio. However, D-dimer and VLDL were negatively associated with prothrombin time. APTT value presented a strong positive association with FBG and LDL, a moderate positive relationship with AIP and TC/HLD. There was a weak positive association between APTT value   HbA1c, D-dimer, PLT, MPV, TC and HDL. However, TG and VLDL were negatively correlated with APTT value.

Highlights:

  1. Metabolic Dysfunction: Hyperglycemia and dyslipidemia increase coagulation factors in diabetes.
  2. Key Findings: Significant rise in PT, APTT, D-dimer, lipid profiles, and MPV.
  3. Correlations: Prothrombin time associates strongly with FBG, PLT, TC, and LDL.

Keywords: diabetes, Prothrombin time, activated partial thromboplastin, atherogenic index of plasma, coagulation factors

View Article

Downloads

Download data is not yet available.

References

  1. . M. Ahmed, N. Chowdhury, G. Sofdar, S. Chakrovortty, M. Rahman, M. Aziz, and A. Rahman, "High fibrinogen level is an independent predictor of presence and severity of coronary artery disease," Cardiovascular Journal, vol. 7, pp. 4-10, 2014.
  2. . O. Alao, D. Damulak, D. Joseph, and F. Puepet, "Haemostatic profile of patients with type 2 diabetes mellitus in Northern Nigeria," The Internet Journal of Endocrinology, vol. 6, pp. 1-4, 2009.
  3. . S. Alzahrani and R. Ajjan, "Coagulation and fibrinolysis in diabetes," Diabetes and Vascular Disease Research, vol. 7, pp. 260-273, 2010.
  4. . B. N. Alzghoul, R. Reddy, M. Chizinga, A. Innabi, B. Zou, E. S. Papierniak, and I. Faruqi, "Pulmonary embolism in acute asthma exacerbation: clinical characteristics, prediction model and hospital outcomes," Lung, vol. 198, pp. 661-669, 2020.
  5. . D. J. Angiolillo, E. Bernardo, M. Sabaté, P. Jimenez-Quevedo, M. A. Costa, J. Palazuelos, R. Hernández-Antolin, R. Moreno, J. Escaned, and F. Alfonso, "Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease," Journal of the American College of Cardiology, vol. 50, pp. 1541-1547, 2007.
  6. . B. Ankalayya, H. Sodhi, S. Modala, and M. Baghel, "A comparative study of coagulation time in type 2 diabetes mellitus and healthy individuals," International Journal of Contemporary Medical Research, vol. 3, pp. 3170-3171, 2016.
  7. . B. A. Bashir and M. S. Ali, "Hemostatic state augmented with platelet indices among Sudanese diabetic septic foot," BMC Hematology, vol. 18, pp. 1-6, 2018.
  8. . G. Boden, "Role of fatty acids in the pathogenesis of insulin resistance and NIDDM," Diabetes, vol. 46, pp. 3-10, 1997.
  9. . W. F. Boron and E. L. Boulpaep, Medical Physiology E-book, Elsevier Health Sciences, 2016.
  10. . A. H. Bryk, M. Konieczyńska, M. Polak, D. Plicner, M. Bochenek, and A. Undas, "Plasma fibrin clot properties and cardiovascular mortality in patients with type 2 diabetes: a long‐term follow‐up study," Cardiovascular Diabetology, vol. 20, pp. 1-11, 2021.
  11. . M.E. Carr, "Diabetes mellitus: a hypercoagulable state," Journal of Diabetes and its Complications, vol. 15, pp. 44-54, 2001.
  12. . P.K. Chaitanya, S. Kavuri, and K.A. Devi, "Comparison of prothrombin time and activated partial thromboplastin time between patients with diabetes mellitus and diabetics with hypertension," Int. J. Ph Bio Sci, vol. 5, pp. 705-709, 2014.
  13. . R. Chilton, J. Wyatt, S. Nandish, R. Oliveros, and M. Lujan, "Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide–1-based therapies," The American Journal of Medicine, vol. 124, pp. S35-S53, 2011.
  14. . M.A. Creager, T.F. Lü­scher, F. Cosentino, and J.A. Beckman, "Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I," Circulation, vol. 108, pp. 1527-1532, 2003.
  15. . M. Dallatu, P. Anaja, L. Bilbis, and F. Mojiminiyi, "Antioxidant micronutrient potentials in strengthening the antioxidant defense in alloxan-induced diabetic rats," Nigerian Journal of Pharmaceutical Sciences, vol. 8, pp. 89-94, 2010.
  16. . H. Ebrahim, F. Asrie, and Z. Getaneh, "Basic coagulation profiles and platelet parameters among adult type 1 and type 2 diabetes patients at Dessie Referral Hospital, Northeast Ethiopia: comparative cross-sectional study," Journal of Blood Medicine, pp. 33-42, 2021.
  17. . M.A. El Asrar, A. Adly, E.S. El Hadidy, and M.A. Abdelwahab, "D-dimer levels in type 1 and type 2 diabetic children and adolescents; Relation to microvascular complications and dyslipidemia—own data and review," Pediatric Endocrinology Reviews, vol. 9, pp. 657-668, 2012.
  18. . J.K. Fadairo, A.D. Atere, T. Ogidiolu, and O. Abiodun, "Assessment of some coagulation indices among type II diabetic subjects in a tertiary facility in South West Region, Nigeria," IOSR-JDMS, vol. 15, pp. 159-163, 2016.
  19. . M.A. Fattah, M.H. Shaheen, and M.H. Mahfouz, "Disturbances of haemostasis in diabetes mellitus," Disease Markers, vol. 19, pp. 251-258, 2003.
  20. . Federation ID, Diabetes Atlas, 6th ed., ISND 2-930229-85-3, 2013. Online version of IDF Diabetes Atlas: www.idf.org.
  21. . M. Gawaz, H. Langer, and A.E. May, "Platelets in inflammation and atherogenesis," The Journal of Clinical Investigation, vol. 115, pp. 3378-3384, 2005.
  22. . S. Gopalakrishnan, G. Anuradha, S. Sumathy, S. Unnikrishnan, and S. Dhanvarshini, "Study to evaluate the correlation between coagulation factor, glycemic control and the severity of diabetic foot ulcers among South Indian population: A case control study," Romanian Journal of Diabetes Nutrition and Metabolic Diseases, vol. 27, pp. 342-348, 2020.
  23. . P. Grant, "Diabetes mellitus as a prothrombotic condition," Journal of Internal Medicine, vol. 262, pp. 157-172, 2007.
  24. . K. Gündogan, F. Bayram, M. Capak, F. Tanriverdi, A. Karaman, A. Ozturk, H. Altunbas, C. Gökce, and A. Kalkan, "Prevalence of metabolic syndrome in the Mediterranean region of Turkey: evaluation of hypertension, diabetes mellitus, obesity, and dyslipidemia," Metabolic Syndrome and Related Disorders, vol. 7, pp. 427-434, 2009.
  25. . V. Gyberg, D. De Bacquer, G. De Backer, C. Jennings, K. Kotseva, L. Mellbin, O. Schnell, J. Tuomilehto, D. Wood, and L. Rydén, "Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology," Cardiovascular Diabetology, vol. 14, pp. 1-11, 2015.
  26. . S. J. Hamilton and G. F. Watts, "Endothelial dysfunction in diabetes: Pathogenesis, significance, and treatment," The Review of Diabetic Studies: RDS, vol. 10, pp. 133, 2013.
  27. . Z. Hekimsoy, B. Payzin, T. Örnek, and G. Kandoğan, "Mean platelet volume in Type 2 diabetic patients," Journal of Diabetes and Its Complications, vol. 18, pp. 173-176, 2004.
  28. . K. Hess, "The vulnerable blood," Hämostaseologie, vol. 35, pp. 25-33, 2015.
  29. . T. Hiraga, M. Shimada, T. Tsukada, and T. Murase, "Hypertriglyceridemia, but not hypercholesterolemia, is associated with the alterations of fibrinolytic system," Hormone and Metabolic Research, vol. 28, pp. 603-606, 1996.
  30. . S. Hörber, R. Lehmann, N. Stefan, J. Machann, A. Birkenfeld, R. Wagner, M. Heni, H. U. Häring, A. Fritsche, and A. Peter, "Hemostatic alterations linked to body fat distribution, fatty liver, and insulin resistance," Molecular Metabolism, vol. 53, p. 101262, 2021.
  31. . L. Horn, W. Pao, D. Johnson, D. Longo, D. Kasper, J. Jamson, A. Fauci, S. Hauser, and J. Loscalzo, Harrison's Principles of Internal Medicine, 18th ed., McGraw-Hill, New York, 2012.
  32. . H. Kaneko, H. Itoh, H. Kiriyama, T. Kamon, K. Fujiu, K. Morita, N. Michihata, T. Jo, N. Takeda, and H. Morita, "Lipid profile and subsequent cardiovascular disease among young adults aged <50 years," The American Journal of Cardiology, vol. 142, pp. 59-65, 2021.
  33. . F. Karim, Q. S. Akter, S. Jahan, A. Khanom, S. Haque, T. Yeasmin, T. Siddika, and S. Sinha, "Coagulation impairment in type 2 diabetes mellitus," Journal of Bangladesh Society of Physiologists, vol. 10, pp. 26-29, 2015.
  34. . D. M. Kendall and A. P. Harmel, "The metabolic syndrome, type 2 diabetes, and cardiovascular disease: Understanding the role of insulin resistance," American Journal of Managed Care, vol. 8, pp. S635-S653, 2002.
  35. . H. Khan, S. Sobki, and S. Khan, "Association between glycaemic control and serum lipids profile in type 2 diabetic patients: HbA1c predicts dyslipidaemia," Clinical and Experimental Medicine, vol. 7, pp. 24-29, 2007.
  36. . H. A. Khan and M. S. Ola, "Markers of blood coagulation, lipid profile, renal function test and serum electrolytes in streptozotocin-induced diabetic rats," Biomed Res-India, vol. 23, pp. 421-424, 2012.
  37. . J. A. Kim, J. E. Kim, S. H. Song, and H. K. Kim, "Influence of blood lipids on global coagulation test results," Annals of Laboratory Medicine, vol. 35, pp. 15, 2015.
  38. . J. H. Kim, H. Y. Bae, and S. Y. Kim, "Clinical marker of platelet hyperreactivity in diabetes mellitus," Diabetes & Metabolism Journal, vol. 37, pp. 423-428, 2013.
  39. . M. A. Laffan and R. Manning, "Investigation of haemostasis," in Dacie and Lewis Practical Haematology, pp. 393-445, Elsevier, 2012.
  40. . H. Lee, J. B. Park, I. C. Hwang, Y. E. Yoon, H. E. Park, S. Y. Choi, Y. J. Kim, G. Y. Cho, K. Han, and H. K. Kim, "Association of four lipid components with mortality, myocardial infarction, and stroke in statin-naïve young adults: A nationwide cohort study," European Journal of Preventive Cardiology, vol. 27, pp. 870-881, 2020.
  41. . B. A. Lemkes, J. Hermanides, J. H. DeVries, F. Holleman, J. C. Meijers, and J. B. Hoekstra, "Hyperglycemia: A prothrombotic factor?" Journal of Thrombosis and Haemostasis, vol. 8, pp. 1663-1669, 2010.
  42. . B. M. Leon and T. M. Maddox, "Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations, and future research," World Journal of Diabetes, vol. 6, pp. 1246, 2015.
  43. . Z. Li, C. Qi, Z. Jia, R. Zhen, L. Ren, Y. Jia, and S. Chen, "The correlation between estimated glucose disposal rate and coagulation indexes in Type 2 diabetes mellitus," Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, pp. 2643-2652, 2022.
  44. . G. Lippi, M. Franchini, G. Targher, M. Montagnana, G. L. Salvagno, G. C. Guidi, and E. J. Favaloro, "Epidemiological association between fasting plasma glucose and shortened APTT," Clinical Biochemistry, vol. 42, pp. 118-120, 2009.
  45. . I. MacFarlane, "Endocrine diseases and diabetes mellitus," in Textbook of Diabetes, pp. 64.61-64.17, 1997.
  46. . K. G. Mann, S. Butenas, and K. Brummel, "The dynamics of thrombin formation," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, pp. 17-25, 2003.
  47. . P. Marchio, S. Guerra-Ojeda, J. M. Vila, M. J. Aldasoro, V. M. Victor, and M. D. Mauricio, "Targeting early atherosclerosis: A focus on oxidative stress and inflammation," Oxidative Medicine and Cellular Longevity, vol. 2019, p. 8563845, 2019.
  48. . I. Martín-Timón, C. Sevillano-Collantes, A. Segura-Galindo, and F. J. del Cañizo-Gómez, "Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength?" World Journal of Diabetes, vol. 5, pp. 444, 2014.
  49. . H. Matcas, "Study on the anomalies of hemostasis on a group of dislipoproteinemia patients," Master's thesis, University of Medicine and Pharmacy, Craiova, 2009.
  50. . E. Morishita, H. Jokaji, and T. Matsuda, "Hyperlipidemia and the hemostatic system," Journal of Atherosclerosis and Thrombosis, vol. 2, pp. S36-S40, 1995.
  51. . N. A. Muhsin and S. S. Al-Mudallal, "Evaluation of plasma fibrinogen, D-dimer, and C-reactive protein as predictive parameters for coronary heart diseases in Type 2 diabetic patients," Mustansiriya Medical Journal, vol. 13, pp. 12, 2014.
  52. . S. W. Mutua, "Evaluation of prothrombin time, international normalized ratio, and activated partial thromboplastin time tests in diabetes mellitus patients at Meru Teaching and Referral Hospital in Kenya," JKUAT-COHES, 2021.
  53. . D. Mylotte, G. Kavanagh, A. Peace, A. Tedesco, D. Carmody, M. O'Reilly, D. Foley, C. Thompson, A. Agha, and D. Smith, "Platelet reactivity in Type 2 diabetes mellitus: A comparative analysis with survivors of myocardial infarction and the role of glycaemic control," Platelets, vol. 23, pp. 439-446, 2012.
  54. . A. Ogedegbe, "An overview of hemostasis," Laboratory Medicine, vol. 33, pp. 948-953, 2002.
  55. . M. O. Omare, J. K. Kibet, J. K. Cherutoi, and F. O. Kengara, "A review of tobacco abuse and its epidemiological consequences," Journal of Public Health, vol. 1, pp. 1-16, 2021.
  56. . J. I. Osende, J. J. Badimon, V. Fuster, P. Herson, P. Rabito, R. Vidhun, A. Zaman, O. J. Rodriguez, E. I. Lev, and U. Rauch, "Blood thrombogenicity in Type 2 diabetes mellitus patients is associated with glycemic control," Journal of the American College of Cardiology, vol. 38, pp. 1307-1312, 2001.
  57. . L. Pan, Y. Ye, M. Wo, D. Bao, F. Zhu, M. Cheng, X. Ni, and X. Fei, "Clinical significance of hemostatic parameters in the prediction for Type 2 diabetes mellitus and diabetic nephropathy," Disease Markers, vol. 2018, 2018.
  58. . M. Pandya, C. Parmar, and M. Singh, "Study of prothrombin time and activated partial thromboplastin time in Type II diabetes mellitus," International Journal of Clinical and Diagnostic Pathology, vol. 3, pp. 173-175, 2020.
  59. . M. Pawelczyk, B. Kaczorowska, and Z. Baj, "The impact of hyperglycemia and hyperlipidemia on plasma P-selectin and sCD40L concentrations in Type 2 diabetes mellitus," Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, vol. 15, pp. 3355-3363, 2022.
  60. . M. Pandya, C. Parmar, and M. Singh, "Study of Prothrombin Time and Activated Partial Thromboplastin Time in Type II Diabetes Mellitus," International Journal of Clinical and Diagnostic Pathology, vol. 3, pp. 173-175, 2020.
  61. . M. Pawelczyk, B. Kaczorowska, and Z. Baj, "The Impact of Hyperglycemia and Hyperlipidemia on Plasma P-Selectin and Platelet Markers after Ischemic Stroke," Arch Med Sci, vol. 13, pp. 1049–1056, 2017.
  62. . P. Poredos and M. K. Jezovnik, "Dyslipidemia, Statins, and Venous Thromboembolism," in Seminars in Thrombosis and Hemostasis, pp. 897-902, Thieme Medical Publishers, 2011.
  63. . U. Ragab, F. O. Selim, A. I. El-Agroody, M. H. E. Mourad, and M. M. Sakr, "The Relationship of Mean Platelet Volume and Atherogenic Index of Plasma with Atherothrombotic Cardiovascular Disease in Diabetes," Romanian Journal of Diabetes Nutrition and Metabolic Diseases, vol. 27, pp. 112-119, 2020.
  64. . H. S. Al-Shaheeb, K. Hashim, A. K. Mohammed, H. A. Almashhadani, and A. Al Fandi, "Assessment of Lipid Profile with HbA1c in Type 2 Diabetic Iraqi Patients," Revis Bionatura, vol. 7, pp. 29, 2022.
  65. . E. Selvin, M. W. Steffes, H. Zhu, K. Matsushita, L. Wagenknecht, J. Pankow, J. Coresh, and F. L. Brancati, "Glycated Hemoglobin, Diabetes, and Cardiovascular Risk in Nondiabetic Adults," New England Journal of Medicine, vol. 362, pp. 800-811, 2010.
  66. . A. L. Soares, M. d. O. Sousa, A. P. S. M. Fernandes, and M. d. G. Carvalho, "Hemostatic Changes in Patients with Type 2 Diabetes Mellitus," Revista Brasileira de Hematologia e Hemoterapia, vol. 32, pp. 482-488, 2010.
  67. . A. I. Sobczak and A. J. Stewart, "Coagulatory Defects in Type-1 and Type-2 Diabetes," International Journal of Molecular Sciences, vol. 20, p. 6345, 2019.
  68. . S. S. Soedamah-Muthu, N. Chaturvedi, M. Toeller, B. Ferriss, P. Reboldi, G. Michel, C. Manes, J. H. Fuller, and the EURODIAB Prospective Complications Study Group, "Risk Factors for Coronary Heart Disease in Type 1 Diabetic Patients in Europe: The EURODIAB Prospective Complications Study," Diabetes Care, vol. 27, pp. 530-537, 2004.
  69. . M. P. Solano and R. B. Goldberg, "Management of Dyslipidemia in Diabetes," Cardiology in Review, vol. 14, pp. 125-135, 2006.
  70. . J. Stamler, O. Vaccaro, J. D. Neaton, D. Wentworth, and the MRFIT Study Group, "Diabetes, Other Risk Factors, and 12-Year Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial," Diabetes Care, vol. 16, pp. 434-444, 1993.
  71. . Y. Takada, T. Urano, I. Watanabe, A. Taminato, T. Yoshimi, and A. Takada, "Changes in Fibrinolytic Parameters in Male Patients with Type 2 (Non-Insulin-Dependent) Diabetes Mellitus," Thrombosis Research, vol. 71, pp. 405-415, 1993.
  72. . S. Thukral, S. Hussain, S. Bhat, N. Kaur, and A. Reddy, "Prothrombin Time (PT) and Activated Partial Thromboplastin Time (APTT) in Type 2 Diabetes Mellitus: A Case Control Study," International Journal of Contemporary Medical Research, vol. 5, pp. H5-H9, 2018.
  73. . K. T. Tonks, C. P. White, J. R. Center, D. Samocha-Bonet, and J. R. Greenfield, "Bone Turnover is Suppressed in Insulin Resistance, Independent of Adiposity," The Journal of Clinical Endocrinology & Metabolism, vol. 102, pp. 1112-1121, 2017.
  74. . D. Toussoules, G. Davies, J. Ambrose, S. C. Tentolouris, and P. Toutouzas, "Effects of Lipids on Thrombotic Mechanisms in Atherosclerosis," International Journal of Cardiology, vol. 86, pp. 239-247, 2002.
  75. . A. Undas, I. Wiek, E. Stêpien, K. Zmudka, and W. Tracz, "Hyperglycemia is Associated with Enhanced Thrombin Formation, Platelet Activation, and Fibrin Clot Resistance to Lysis in Patients with Acute Coronary Syndrome," Diabetes Care, vol. 31, pp. 1590-1595, 2008.
  76. . V. R. Vaidyula, A. K. Rao, M. Mozzoli, C. Homko, P. Cheung, and G. Boden, "Effects of Hyperglycemia and Hyperinsulinemia on Circulating Tissue Factor Procoagulant Activity and Platelet CD40 Ligand," Diabetes, vol. 55, pp. 202-208, 2006.
  77. . H. Wada, Y. Mori, T. Kaneko, Y. Wakita, K. Minamikawa, M. Ohiwa, S. Tamaki, N. Yokoyama, T. Kobayashi, and K. Deguchi, "Hypercoagulable State in Patients with Hypercholesterolemia: Effects of Pravastatin," Clinical Therapeutics, vol. 14, pp. 829-834, 1992.
  78. . X. C. Xiangyu, F. Le, H. L. Hongbo, S. Peng, T. Zhang, L. Hui, L. Xiaoyong, Y. Min, X. Chunxiao, and J. Zhang, "The Relationship between Type 2 Diabetes and Platelet Indicators," Iranian Journal of Public Health, vol. 46, pp. 1211, 2017.
  79. . W. Yang, S. Ren, and J. Liang, "Application and Effect of High-Quality Nursing Combined with Enteral Nutrition Support in Patients with Acute Pancreatitis," J. Mod. Nurs. Pract. Res., vol. 1, pp. 1, 2021.
  80. . A. Zaidi and L. Green, "Physiology of Haemostasis," Anaesthesia & Intensive Care Medicine, vol. 20, pp. 152-158, 2019.
  81. . Y. Zhang, R. Chen, Y. Jia, M. Chen, and Z. Shuai, "Effects of Exenatide on Coagulation and Platelet Aggregation in Patients with Type 2 Diabetes," Drug Design, Development and Therapy, pp. 3027-3040, 2021.